Published in Mol Pathol on June 01, 2000
Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A (2001) 4.60
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol (2005) 2.25
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer (2009) 1.33
Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia (2008) 1.32
Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res (2003) 1.19
miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget (2015) 0.93
Inactivation of SLIT2-ROBO1/2 pathway in premalignant lesions of uterine cervix: clinical and prognostic significances. PLoS One (2012) 0.82
BPDE induced lymphocytic chromosome 3p deletions may predict renal cell carcinoma risk. J Urol (2008) 0.81
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell (1996) 15.19
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71
Clinical features and natural history of von Hippel-Lindau disease. Q J Med (1990) 4.71
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res (1994) 3.62
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (1987) 3.46
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol (1998) 3.30
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
von Hippel-Lindau disease. Medicine (Baltimore) (1997) 2.89
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77
Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet (1994) 2.65
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer (1998) 2.27
Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract (1986) 2.19
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res (1996) 2.10
Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc Natl Acad Sci U S A (1999) 1.78
Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res (1997) 1.76
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A (1988) 1.76
The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res (1996) 1.75
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res (1997) 1.66
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet (1997) 1.54
Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A (1996) 1.48
Homozygous deletions at 3p12 in breast and lung cancer. Oncogene (1998) 1.42
Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene (1998) 1.38
3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol Cell Biol (1996) 1.25
Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci U S A (1992) 1.24
Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics (1990) 1.18
A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene (1993) 1.16
A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci U S A (1994) 1.09
Mapping of the von Hippel-Lindau disease locus to a small region of chromosome 3p by genetic linkage analysis. Genomics (1991) 1.09
The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta (1997) 1.07
A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Res (1994) 1.02
Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. Cancer Res (1998) 0.96
Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. Genes Chromosomes Cancer (1996) 0.92
Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv (1995) 0.92
Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma. Cancer Genet Cytogenet (1988) 0.91
The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. Cancer Res (1999) 0.88
Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Genes Chromosomes Cancer (1999) 0.88
Molecular characterization of a large homozygous deletion in the small cell lung cancer cell line U2020: a strategy for cloning the putative tumor suppressor gene. Genes Chromosomes Cancer (1992) 0.83
The human homolog of the rodent immediate early response genes, PC4 and TIS7, resides in the lung cancer tumor suppressor gene region on chromosome 3p21. Hum Genet (1997) 0.81
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 22.06
Isolation and regional localization of a large collection (2,000) of single-copy DNA fragments on human chromosome 3 for mapping and cloning tumor suppressor genes. Hum Genet (1991) 12.52
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology (1970) 6.06
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem (2000) 5.58
Infectious immunological tolerance. Immunology (1971) 5.30
Embryonic stem cells express neuronal properties in vitro. Dev Biol (1995) 5.03
Redox-coupled crystal structural changes in bovine heart cytochrome c oxidase. Science (1998) 5.01
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
A neomycin resistance gene cassette selectable in a single copy state in the Bacillus subtilis chromosome. Nucleic Acids Res (1989) 3.87
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res (1994) 3.62
A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A (1999) 3.37
Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta-analysis. Ultrasound Obstet Gynecol (2013) 3.28
Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet (1994) 3.04
Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92
Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat (1995) 2.91
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.63
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet (2001) 2.56
Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet (1994) 2.52
Beckwith-Wiedemann syndrome and assisted reproduction technology (ART). J Med Genet (2003) 2.48
Dietary variety within food groups: association with energy intake and body fatness in men and women. Am J Clin Nutr (1999) 2.45
Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet (1999) 2.41
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.36
Antigenic competition between heterologous erythrocytes. I. Thymic dependency. J Immunol (1971) 2.35
Immuno-regulatory role of spleen localizing thymocytes. J Immunol (1974) 2.27
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer (1998) 2.27
Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. Hum Mol Genet (1995) 2.27
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Inhibition of LDL oxidation by cocoa. Lancet (1996) 2.16
Molecular cloning and nucleotide sequence of the cDNA for rat peroxisomal enoyl-CoA: hydratase-3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme. J Biol Chem (1985) 2.12
Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res (2001) 2.12
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci U S A (1981) 2.10
Pharmacological response of internal mammary artery and gastroepiploic artery. Ann Thorac Surg (1990) 2.04
Aggravation of subclinical diabetes insipidus during pregnancy. N Engl J Med (1991) 2.03
Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome. Trends Genet (1997) 2.01
The structure of inducing factors for virginiamycin production in Streptomyces virginiae. J Antibiot (Tokyo) (1987) 1.99
Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer (2002) 1.95
The VHL tumour-suppressor gene paradigm. Trends Genet (1998) 1.94
Structure and functional analysis of a marine bacterial carotenoid biosynthesis gene cluster and astaxanthin biosynthetic pathway proposed at the gene level. J Bacteriol (1995) 1.90
Case-control studies of motor neuron disease: association with mechanical injuries. Arch Neurol (1981) 1.89
Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene (2007) 1.86
Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. Ultrasound Obstet Gynecol (2011) 1.85
Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol (2006) 1.84
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. J Biol Chem (1999) 1.82
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene (1995) 1.82
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
The genetics of paragangliomas: a review. Clin Otolaryngol (2007) 1.77
Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med (1984) 1.76
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther (1998) 1.74
Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet (1999) 1.74
Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res (1994) 1.73
Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene (2010) 1.69
Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet (2003) 1.68
Beckwith-Wiedemann syndrome. J Med Genet (1994) 1.67
Resting and active properties of pyramidal neurons in subiculum and CA1 of rat hippocampus. J Neurophysiol (2000) 1.66
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res (1999) 1.65
Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol (1999) 1.64
Germline SDHD mutation in familial phaeochromocytoma. Lancet (2001) 1.62
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost (2008) 1.62
A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61
Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology (2008) 1.60
CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem (1997) 1.60
On concomitant immunity in tumour-bearing hamsters. Nature (1967) 1.59
From embryonal carcinoma cells to neurons: the P19 pathway. Bioessays (1994) 1.58
Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. Hum Mol Genet (1996) 1.57
Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway. Hum Mol Genet (1996) 1.57
Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci U S A (1992) 1.56
Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol (R Coll Radiol) (2013) 1.56
The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1986) 1.55
Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. Hum Mol Genet (1997) 1.54
Detection of varicella-zoster virus (VZV) DNA in clinical samples from patients with VZV by the polymerase chain reaction. J Clin Microbiol (1991) 1.54
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet (1997) 1.54
A study of ruptured tubal ectopic pregnancy. Obstet Gynecol (1997) 1.53